Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Elacestrant Monotherapy for the Treatment of Japanese Participants With ER+/HER2- Advanced or Metastatic Breast Cancer With ESR1-mutation Following CDK4/6 Inhibitor Therapy

NCT07766018 is registered in ClinicalTrials.gov with Stemline Therapeutics, Inc. as lead sponsor.

NCT NCT07766018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07766018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Elacestrant Monotherapy for the Treatment of Japanese Participants With ER+/HER2- Advanced or Metastatic Breast Cancer With ESR1-mutation Following CDK4/6 Inhibitor Therapy
Lead sponsor
Stemline Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 18, 2026
Completion date
October 31, 2028
Enrollment
70 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer